UT Southwestern NCI National Clinical Trials Network (NCTN) LAPS - Supplemental Funds YR4
UT 西南 NCI 国家临床试验网络 (NCTN) LAPS - 补充资金 YR4
基本信息
- 批准号:10733732
- 负责人:
- 金额:$ 4.53万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-05-22 至 2023-02-28
- 项目状态:已结题
- 来源:
- 关键词:Academic Medical CentersAdultAfrican AmericanAreaAwardBasic ScienceBioinformaticsCancer CenterCategoriesClinicClinical InvestigatorClinical ResearchClinical TrialsClinical Trials NetworkComprehensive Cancer CenterConduct Clinical TrialsCountryDiseaseEligibility DeterminationEnrollmentFacultyFundingGrantGrowthHispanicHospitalsImageLeadLeadershipMalignant NeoplasmsMalignant neoplasm of lungMedical centerMentorsNational Clinical Trials NetworkOutcomes ResearchParentsPatient-Focused OutcomesPatientsPopulationPopulation HeterogeneityPositioning AttributePublicationsRaceRecording of previous eventsRenal carcinomaResearchRoleSiteTexasTherapeuticTimeTranslatingUniversitiesbasecareer developmentclinical trial enrollmentcostdesigndrug discoveryethnic diversityethnic minorityinnovationmedical schoolsmembermetropolitanparticipant enrollmentpressureprogramsracial minorityscreeningtimeline
项目摘要
PROJECT SUMMARY/ABSTRACT (from UG1CA233302 parent award)
For years, the University of Texas Southwestern Medical Center (UTSW) has provided key leadership within
the National Clinical Trials Network (NCTN). The leaders of this UG1 application and other faculty members
hold major NCTN roles, including chairing clinical trials and committees. From March 2014 through August
2017, UTSW enrolled 520 patients on adult NCTN trials across 13 disease categories. During that time, UTSW
faculty authored or co-authored 27 publications directly related to NCTN trials, and have chaired, co-chaired, or
served as cooperative group committee chairs on 13 cooperative group trials. Substantial recent growth
positions UTSW to expand accrual and scientific contributions. After receiving initial NCI designation in 2010,
the Harold C. Simmons Cancer Center received comprehensive designation in 2015. Since 2015, two new
hospitals affiliated with UTSW have been constructed. We have a vibrant drug discovery program; SPORE
grants in lung cancer and kidney cancer; an Advanced Imaging Research Center; and a Patient Centered
Outcomes Research (PCOR) Center. As the only academic medical center and medical school in the
Dallas/Ft. Worth (DFW) Metroplex (population 7.2 million) and the only NCI-designated Comprehensive Cancer
Center in North Texas, UTSW reaches a large and diverse population that otherwise would not have access to
NCTN trials. In recent years, up to 29% of our patients enrolled on NCTN clinical studies were Hispanic, and
up to 21% were African American. The specific aims of the UTSW UG1 are the following: Aim 1. Contribute
to NCTN trial accrual. We will continue to enroll patients with diverse ethnic and racial backgrounds on
therapeutic and non-therapeutic trials. Aim 2. Contribute to NCTN scientific direction. We will bring UTSW
basic, translational, and imaging research into hypothesis-driven clinical trials. Aim 3. Provide NCTN
leadership. UTSW faculty will continue to chair and co-chair clinical trials and committees in the various
NCTN groups, and by participate in NCI activities and initiatives. Aim 4. Promote career development of
junior faculty and trainees. UTSW faculty will provide mentoring and guidance in the NCTN. Aim 5. Support
NCTN administrative efforts. UTSW faculty will continue to serve on NCTN and NCI regulatory and auditing
committees. At multiple steps, the design and conduct of cancer clinical research has become more
challenging. Financial pressures have limited the protected time of clinical investigators nationwide. Increasing
cost and complexity of clinical trials has prolonged activation timelines and restricted eligibility. UTSW is poised
to meet and overcome these challenges. With designated funding and mentoring programs, we continue to
develop clinical investigators and disease experts. We have capitalized on a large and diverse patient base, as
well as growing bioinformatics capabilities, to optimize the identification, screening, and enrollment of clinical
trial subjects. Together, these approaches position UTSW to continue to help lead and expand NCTN efforts.
项目总结/摘要(来自UG 1CA 233302母公司合同)
多年来,德克萨斯大学西南医学中心(UTSW)在内部提供了关键领导
国家临床试验网络(NCTN)。UG 1应用程序的领导者和其他教职员工
担任主要的NCTN角色,包括主持临床试验和委员会。2014年3月至8月
2017年,UTSW在13个疾病类别的成人NCTN试验中招募了520名患者。在此期间,UTSW
教师撰写或共同撰写了27篇与NCTN试验直接相关的出版物,并主持,共同主持,或
在13次合作小组试验中担任合作小组委员会主席。近期大幅增长
使UTSW能够扩大应计和科学贡献。在2010年获得最初的NCI认定后,
哈罗德C。西蒙斯癌症中心于2015年获得全面指定。自2015年以来,两个新
附属于南威尔士大学的医院已经建成。我们有一个充满活力的药物发现计划;孢子
肺癌和肾癌的赠款;一个先进的成像研究中心;和一个以患者为中心的
成果研究中心。作为美国唯一的学术医疗中心和医学院,
达拉斯/英尺沃思(DFW)大都会(人口720万)和唯一的NCI指定的综合癌症
中心在北德克萨斯州,UTSW达到了一个庞大而多样化的人口,否则将无法获得
NCTN试验。近年来,在NCTN临床研究中,高达29%的患者是西班牙裔,
21%是非洲裔美国人。UTSW UG 1的具体目标如下:目标1。贡献
NCTN试验累积。我们将继续招募具有不同种族和种族背景的患者,
治疗和非治疗试验。目标二。为NCTN的科学方向做出贡献。我们将带来UTSW
基础、转化和影像学研究转化为假设驱动的临床试验。目标3.提供NCTN
领导UTSW教师将继续主持和共同主持临床试验和委员会在各种
NCTN团体,并参与NCI的活动和倡议。目标4。促进职业发展
初级教员和实习生UTSW教师将在NCTN提供指导和指导。目标5。支持
NCTN的行政工作。UTSW教师将继续在NCTN和NCI监管和审计部门任职
委员会。在多个步骤中,癌症临床研究的设计和实施变得更加复杂。
挑战性财政压力限制了全国范围内临床研究者的受保护时间。增加
临床试验的成本和复杂性延长了激活时间表并限制了资格。UTSW蓄势待发
来迎接和克服这些挑战。通过指定的资金和指导计划,我们将继续
培养临床研究人员和疾病专家。我们利用了庞大而多样化的患者基础,
以及不断增长的生物信息学能力,以优化临床
试验对象。总之,这些方法使UTSW能够继续帮助领导和扩大NCTN的工作。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
David Eric Gerber其他文献
David Eric Gerber的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('David Eric Gerber', 18)}}的其他基金
Finding the optimal balance of immunotherapy efficacy and toxicity.
寻找免疫治疗功效和毒性的最佳平衡。
- 批准号:
10630125 - 财政年份:2020
- 资助金额:
$ 4.53万 - 项目类别:
Finding the optimal balance of immunotherapy efficacy and toxicity.
寻找免疫治疗功效和毒性的最佳平衡。
- 批准号:
10418693 - 财政年份:2020
- 资助金额:
$ 4.53万 - 项目类别:
Finding the optimal balance of immunotherapy efficacy and toxicity.
寻找免疫治疗功效和毒性的最佳平衡。
- 批准号:
9921601 - 财政年份:2020
- 资助金额:
$ 4.53万 - 项目类别:
Finding the optimal balance of immunotherapy efficacy and toxicity.
寻找免疫治疗功效和毒性的最佳平衡。
- 批准号:
10376977 - 财政年份:2020
- 资助金额:
$ 4.53万 - 项目类别:
Finding the optimal balance of immunotherapy efficacy and toxicity.
寻找免疫治疗功效和毒性的最佳平衡。
- 批准号:
10189523 - 财政年份:2020
- 资助金额:
$ 4.53万 - 项目类别:
UT Southwestern NCI National Clinical Trials Network Lead Academic Site
UT 西南 NCI 国家临床试验网络领先学术网站
- 批准号:
10359155 - 财政年份:2019
- 资助金额:
$ 4.53万 - 项目类别:
UT Southwestern NCI National Clinical Trials Network Lead Academic Site
UT 西南 NCI 国家临床试验网络领先学术网站
- 批准号:
10062108 - 财政年份:2019
- 资助金额:
$ 4.53万 - 项目类别:
UT Southwestern NCI National Clinical Trials Network Lead Academic Site
UT 西南 NCI 国家临床试验网络领先学术网站
- 批准号:
10581694 - 财政年份:2019
- 资助金额:
$ 4.53万 - 项目类别:
Evaluating prior cancer exclusion policy to increase lung cancer trial accrual
评估先前的癌症排除政策以增加肺癌试验的应计数量
- 批准号:
9108931 - 财政年份:2015
- 资助金额:
$ 4.53万 - 项目类别:
UT Southwestern NCI National Clinical Trials Network Lead Academic Site - U10
UT 西南 NCI 国家临床试验网络主要学术网站 - U10
- 批准号:
9248972 - 财政年份:2014
- 资助金额:
$ 4.53万 - 项目类别:
相似海外基金
A neuroimaging approach to advance mechanistic understanding of tobacco use escalation risk among young adult African American vapers
一种神经影像学方法,可促进对年轻非洲裔美国电子烟使用者烟草使用升级风险的机制理解
- 批准号:
10509308 - 财政年份:2022
- 资助金额:
$ 4.53万 - 项目类别:
Understanding social undermining of weight management behaviors in young adult African American women
了解年轻非洲裔美国女性体重管理行为的社会破坏
- 批准号:
10680412 - 财政年份:2022
- 资助金额:
$ 4.53万 - 项目类别:
Understanding social undermining of weight management behaviors in young adult African American women
了解年轻非洲裔美国女性体重管理行为的社会破坏
- 批准号:
10535890 - 财政年份:2022
- 资助金额:
$ 4.53万 - 项目类别:
A neuroimaging approach to advance mechanistic understanding of tobacco use escalation risk among young adult African American vapers
一种神经影像学方法,可促进对年轻非洲裔美国电子烟使用者烟草使用升级风险的机制理解
- 批准号:
10629374 - 财政年份:2022
- 资助金额:
$ 4.53万 - 项目类别:
Impact of Adult Day Services on Psychosocial and Physiological Measures of Stress among African American Dementia Family Caregivers
成人日间服务对非裔美国痴呆症家庭护理人员的社会心理和生理压力测量的影响
- 批准号:
10553725 - 财政年份:2021
- 资助金额:
$ 4.53万 - 项目类别:
Voice-Activated Technology to Improve Mobility & Reduce Health Disparities: EngAGEing African American Older Adult-Care Partner Dyads
语音激活技术可提高移动性
- 批准号:
10494191 - 财政年份:2021
- 资助金额:
$ 4.53万 - 项目类别:
Impact of Adult Day Services on Psychosocial and Physiological Measures of Stress among African American Dementia Family Caregivers
成人日间服务对非裔美国痴呆症家庭护理人员的社会心理和生理压力测量的影响
- 批准号:
10328955 - 财政年份:2021
- 资助金额:
$ 4.53万 - 项目类别:
Voice-Activated Technology to Improve Mobility & Reduce Health Disparities: EngAGEing African American Older Adult-Care Partner Dyads
语音激活技术可提高移动性
- 批准号:
10437374 - 财政年份:2021
- 资助金额:
$ 4.53万 - 项目类别:
Voice-Activated Technology to Improve Mobility & Reduce Health Disparities: EngAGEing African American Older Adult-Care Partner Dyads
语音激活技术可提高移动性
- 批准号:
10654831 - 财政年份:2021
- 资助金额:
$ 4.53万 - 项目类别:
Development, Implementation, and Evaluation of a Smoking Cessation Intervention Tailored to Rural Young Adult African American Men: Toward Scalability
针对农村年轻非裔美国男性的戒烟干预措施的制定、实施和评估:走向可扩展性
- 批准号:
9896786 - 财政年份:2018
- 资助金额:
$ 4.53万 - 项目类别: